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Despite a voluminous literature on potential protein biomarkers and a compelling need for di-
agnostic tests based on biomarkers to detect cancers at much earlier, more treatable stages, pro-
gress has been limited. New methods and new instruments for analysis of differences in gene
expression, gene methylation, and proteomics are being employed to try to accelerate the dis-
covery phase. Given the heterogeneity of tumor mechanisms and the limitations of analytical
methods, it is likely that a variety of strategies will be needed and will be complementary. That is
the basis of this review of proteomic approaches. This article adopts a systems biology view,
starting with mRNA transcripts in tumors and cultured tumor cells to detect mRNA over-
expression, some of which will be correlated with protein overexpression. Some of those proteins
may be secreted or released into proximal biofluids and plasma. Detection of low-abundance
tumor proteins in the complex and dynamic mixture that is plasma requires combinations of
increasingly powerful technologies. The biological amplification of protein signals through the
immune system offers autoantibodies as potential biomarkers. Higher abundance proteins,
including acute-phase reactants, may have practical value, especially if the proteins are modified
as part of the cancer processes. Low molecular weight proteins, fragments, and peptides may
offer complementary biomarkers. Promising biomarker candidates must be confirmed in inde-
pendent studies. Then they must be submitted to higher-throughput methods practical for large-
scale validation studies and, hopefully, for clinical and epidemiological applications. Standard-
ized operating procedures for specimen handling, design and use of various reference standards,
care to avoid bias and confounding, and guidelines for reporting findings and contributing
datasets should enhance the prospects for predictive proteomic profiling of people at risk for
cancers.
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1 Introduction
Molecular biology has emerged during the past six decades
with dramatic step functions in our knowledge. In 1944,
Avery et al. demonstrated that DNA, not proteins, carries the
information for inherited traits. In 1953, the x-ray diffraction
results of Franklin and Wilkins inspired Watson and Crick to
propose the hydrogen-bonded, double-helix structure for
DNA and its replication. In the 1960s, Nirenberg and others
demonstrated that a triplet code of nucleotide bases (A, T, G,
C) specified, via translational mechanisms, the amino acid
sequences in proteins. In the 1970s, came recombinant DNA
and later the polymerase chain reaction (PCR) amplification
of DNA. In the 1980s, the Human Genome Program was
formulated and initiated, to greatly improve DNA and pro-
tein sequencing and synthesizing technologies, create
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methods for mapping DNA segments, and then conduct
huge-scale genome sequencing. Nearly complete human ge-
nome results were published 15–16 February 2001 in special
issues of Science and Nature.
We have ushered in a “new world” of biology, genetics,
and biotechnology–employing genome expression micro-
arrays, comparative genomics, proteomics, and bioinfor-
matics to seek to understand a great variety of diseases and
eventually to transform medical care into a predictive, per-
sonalized, and preventive future model. Analytical instru-
ments and bioinformatics have made experiments pre-
viously infeasible quite conceivable and increasingly feasible.
The aims of proteomic analyses of tumors and of plasma
or serum from cancer patients are outlined in Table 1. The
rationale for proteomic profiling is based on the fact that
proteins are much closer to the pathophysiological changes
in disease than are mRNAs. Up-regulated or modified pro-
teins may themselves be molecular targets for drugs.
Advances in fractionation of complex tissue and plasma pro-
tein mixtures, MS and antibody-based assays, and curated
databases of proteins increasingly address the challenges of
complexity, dynamic range, and incompleteness and uncer-
tainty of protein identifications. Repositories with extensive
datasets on normal protein findings include combined
resources in UniProt and the International Protein Index
managed by the European Bioinformatics Institute (www.
ebi.ac.uk) and those from the Human Proteome Organization
(HUPO) Plasma Proteome Project [1], which are publicly
accessible at www.ebi.ac.uk/pride, www.bioinformatics.
med.umich.edu/hupo/ppp, and www.peptideatlas.org.
Table 1. Aims of proteomics analyses of specimen from cancer
patients
1. Profile tumor specimens for diagnosis and stratification
of patients
2. Profile tumor specimens for prognosis with particular
therapies
3. Discover and validate circulating proteins as biomarkers
for earlier diagnosis
4. Apply such biomarkers to predict/monitor response to
treatment and recurrence
Examining all genes and large numbers of proteins
simultaneously, instead of one gene or one protein at a time,
facilitates a systems biology approach to investigation of
pathways, modules, regulatory networks, and responses to
all kinds of perturbations [2]. In addition to yeast, C. elegans,
Halobacterium and sea urchin models, these applications
are most evident in cancer research [3], reflecting the somatic
genetic basis for cancers and the desire to identify and vali-
date new targets for more effective chemotherapy.
At the clinical and population level, common cancers
remain largely unsolved medical problems. As shown in
Table 2, according to the American Cancer Society 550 000
Table 2. Cancers remain largely unsolved medical problems




Lung 171 900 157 200
Colorectal 147 500 57 100
Breast 211 300 39 800
Prostate 220 900 28 900
Pancreas 30 700 30 000
Ovarian 25 400 14 300
Total 2 000 000 550 000
Source: American Cancer Society
Americans die of various cancers each year. Lung cancers
and pancreatic cancers remain extremely lethal, as deaths
nearly equal incident cases, with short survival times. The
poor outcomes of treatment for patients with lung cancers
can be understood with Fig. 1, showing the relationship of
tumor growth in doublings and volume to the late appear-
ance of symptoms, later than the spread of metastases in
most cases. The bottleneck on improving survival results
with cancer therapies clearly lies in much earlier diagnosis.
As shown in Table 3, even with present treatments, 5-year
survival rates are far higher for patients whose lung, colo-
rectal, breast, or prostate cancers are diagnosed while the
tumor is still localized. Molecular biomarkers, primarily
proteins, are the key to such earlier diagnoses, combined
with imaging for localization.
An approach using molecular signatures and molecular
mechanisms of cancers also offers a potential solution to the
“pharmacogenomic nightmare” of the pharmaceutical com-
panies. Currently, a drug that shows efficacy against, say,
lung cancers, may be utilized in up to all of the 170 000
patients diagnosed annually with lung cancers in the U.S.
alone. If molecular stratification of patients shows only
5–20% of patients have specific amplification or over-
Figure 1. Schema of growth of the primary lung cancer, devel-
opments of metastases, and very late appearance of symptoms
sufficient to consider the diagnosis (kindly provided by Pierre
Masson, Vanderbilt University).
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Table 3. Detecting cancers early dramatically increases survival
Cancers 5-year survival rates





Source: American Cancer Society
expression or mutation of genes and receptors against which
a particular drug is targeted, then the market would be
reduced accordingly. This is true for human epidermal
growth factor receptor 2 (HER2/neu) overexpression in cer-
tain breast cancers and mutated EGF-receptor tyrosine
kinase domain in certain lung cancers. There is emerging
evidence that similar mutations occur in some other tumors.
If the same molecular signatures and mechanisms could be
identified in, say, 5–20% of other common adenocarcinomas
(colorectal, prostate, breast, lung, pancreas), then the com-
bined market might be substantial and the efficacy:toxicity
ratio would be greatly enhanced. There may still be other
malignancies where the proportion of patients treatable with
a particular agent will be very high, as with imatinib mesylate
(Gleevec) targeted at bcr-abl translocations in Ph1-positive
chronic myelogenous leukemias. However, the percentage of
total leukemia patients is low. If the target is common in a
tumor type, as appears to be the case in the majority of pros-
tate cancers with the remarkable TMPRSS2/ETS fusion
genes, which make ETS family transcription factors ERG
and ETV1 androgen responsive [4], then new drugs, yet to be
discovered, might have a benefit for that high proportion of
patients. Conversely, if the target is common for multiple
tumors, like VEGF-mediated angiogenesis, an anti-VEGF
drug might be useful for patients with a variety of tumor
types. Specific diagnostic tests are needed for each molecu-
larly-targeted treatment.
This is an optimistic scenario. Molecularly targeted drugs
are still few, despite vast investment in drug discovery and
clinical trials. And new diagnostic tests have been very few, as
well [5]. One reason is the marked heterogeneity of cancers
even of the same organ of origin or similar histology.
Another is the failure to characterize the positive predictive
value for the test in relevant clinical scenarios before intro-
ducing the test for clinical use. Two of the most widely used
tests–PSA and CA-125–have poor sensitivity and specificity,
and thus low predictive value, for screening; however, they
are useful for monitoring already-diagnosed patients for
recurrence. According to Ludwig and Weinstein [6], despite
6000–8000 Medline entries for “cancer-related biomarkers”
during each of the years 1999 through 2003, the total number
of FDA-approved new tests was 2. Finding and validating
new biomarkers has proved very difficult.
The cumulative roster of tests is limited to a-fetoprotein
for liver, b-HCG for testicular, CA-19–9 for pancreatic, CA-
125 for ovarian, carcioembryonic antigen (CEA) and EGFR
for colon, KIT for GIST, thyroglobulin for thyroid, PSA for
prostate; CA-15–3, CA-27–29, cytokeratins, ER/PR, and
HER2/neu (aka ErbB2) for breast; and five for bladder can-
cers. Only Pap smears for cervical, PSA for prostate, and
FISH/chromosome sites and NMP22 for bladder have been
approved for screening, as opposed to monitoring already
diagnosed patients for treatment response or recurrence.
Each was approved as an “analyte-specific” assay [6].
Thus, there is a great need for new biomarkers, probably
groups or panels of biomarkers to cover the expected hetero-
geneity of any common condition. One approach is to start
from the biology of the cancers; another approach is to com-
pare plasma or serum protein patterns in groups of patients
and controls. With more sensitive instruments and emerg-
ing methods to fractionate and detect proteins and PTMs of
proteins, these approaches should become more productive.
No single approach is likely to detect the variety of paths that
may yield useful biomarkers.
2 Discovering, confirming, and validating
protein biomarkers
2.1 Starting from gene expression molecular profiles
of tumors
There is a large literature on mRNA gene expression chang-
es in tumors, compared with normal tissue and compared
with non-malignant pathology in the same organs. A well-
annotated resource for this literature is www.oncomine.org
[7] (Fig. 2). The changes in gene expression in tumors can be
organized into phenomena, as in Hanahan and Weinberg’s
“hallmarks of cancer” [8] (Table 4) and into functional
groupings of differentially expressed mRNAs and proteins,
as with prostate cancers (Fig. 3). These latter studies led to
identification (and licensing) of hepsin, a-methylacyl-CoA
racemase (AMACR) [9], and the polycomb protein transcrip-
tion factor EZH2 [10] as promising biomarker candidates for
prostate cancer diagnosis and prognosis. EZH2 over-
expression in the tumor by immunohistochemistry is highly
correlated with metastatic versus localized prostate cancers
and with poorer survival [10].
Table 4. Hallmarks of the pathogenesis of cancers [8]
1. Self sufficiency in growth signals
2. Insensitivity to anti-growth signals
3. Evasion of apoptosis
4. Tissue invasion and metastasis
5. Sustained angiogenesis
6. Limitless replicative potential.
Also, DNA repair and genomic instability
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Figure 2. Oncomine, a micro-
array database for cancer
(www.oncomine.org).
Figure 3. Summary of gene
expression changes by protein
functional classes during pros-
tate cancer progression (pro-
vided by A. Chinnaiyan, Uni-
versity of Michigan).
These classifications of the molecular profiles of tumors
move beyond lists of genes (or proteins) toward pathways
and networks up-regulated or down-regulated over time
during the initiation and progression of tumors. Such find-
ings can be related to changes in cultured cells, xenografts,
and patients with specific drug or siRNA interventions, and
can be confirmed with direct detection and quantitation of
proteins in the tumor tissue. Variation in tumors due to
inherited genomic differences, including single nucleotide
polymorphisms; somatic chromosomal changes, including
translocations; and epigenetic modifications, especially
methylation (5-methyl-cytosine) of DNA, are additional
important levels of characterization of tumors. However,
while changes in some mRNA/protein pairs are pretty well
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correlated, mRNA changes, overall, have surprisingly low
correlation with changes in the corresponding proteins. This
discrepancy presumably reflects the many post-translational
events affecting protein structure, function, activation, and
degradation. For example, Beer et al. [11] reported from a
comparison of 76 human lung adenocarcinomas and 9 non-
neoplastic lung specimens that 28 of 165 proteins identified
by MS had a statistically significant correlation (r.0.24;
p,0.05) with mRNA expression profiles in the same speci-
mens; among all 165 proteins, r values ranged from 20.47 to
10.44. Since proteins may have numerous isoforms, it is
quite complex to compare mRNA and protein concentrations
from very different methods. Different isoforms of pre-
sumably the same protein may differ in correlations with the
mRNA. In the Beer study, 20 tumor-associated proteins were
utilized to create a risk index for stage I patients, permitting
elucidation of two subgroups with regard to survival, one
with excellent 8-year survival, and the other with con-
siderably poorer survival, more typical of more advanced
lung cancer patients [12].
Varmabally et al. [13] used high-throughput immuno-
blotting of tissue extracts derived from prostate cancers; they
identified 64 proteins altered in prostate cancer, compared
with benign prostate hypertrophy, and 156 additional pro-
teins altered in metastatic disease, compared with localized
prostate cancer. Overall there was 48–64% concordance be-
tween protein and transcript expression level changes. Pre-
dictors of metastatic disease applied not just to prostate can-
cers, but to other solid tumors, as well.
It is useful to predict from the sequence features of cor-
responding proteins, and verify by direct measurement,
which proteins will be secreted by tumor cells into the extra-
cellular compartment and appear in lymph, other proximal
fluids of specific organs, and, after huge dilution, the blood
plasma. Targeted analysis of these biofluids for the expected
proteins would depend then on the sensitivity of the method
and the concentration of the protein, its stability and half-life,
and any modifications of the protein that affect its detect-
ability.
Direct analysis of tumors and of tumor cells fractionated
by laser microdissection to permit analysis of the marked
cellular heterogeneity of tumor masses may help reveal pro-
tein changes in tumors. There is a large literature of papers
using 2-DE, now enhanced with paired analysis using fluo-
rescent Cy dyes (DIGE). Most of the resulting papers report
rather small numbers of proteins, as expected from the lim-
ited sensitivity of the gel-based method. However, Xiao et al.
[14] identified 299 proteins in conditioned media of primary
lung cancer or cell line cultures; 11 of 13 that were chosen for
pilot ELISAs were detected in plasma.
After the tumor itself, it is logical to search for targeted
proteins or conduct a general proteomic analysis of proximal
biofluids [15]. These include urine for bladder and kidney
cancers [16]; cerebrospinal fluid for brain tumors and other
brain disorders [17]; nipple aspirate, ductal lavage, or inter-
stitial fluid for breast tumors [18, 19]; pancreatic and bile
fluids for pancreatic and liver cancers; saliva for parotid and
other salivary gland tumors; broncho-alveolar lavage or
pleural effusion for lung cancers [20]; and prostatic aspirate,
seminal fluid [21], tears, and other biofluids. However, we
should note the complexity of transport or diffusion of
molecules from the interstitium to the circulation. The
endothelial cell is an effective barrier to most proteins above
40 kDa, so large proteins that are secreted may not actually
make their way to the blood, at least not as intact proteins.
Studies of such specimens, even in very small volumes, may
be feasible with animal models of various human cancers.
The Mouse Models of Human Cancers Consortium of the
U.S. National Cancer Institute has multiple promising mod-
els, created with mutations discovered first in corresponding
human cancers, such as the Apc (adenomatous polyposisoli)
min/1 mouse with intestinal tumors (see http://emice.nci.
nih.gov/mouse_models). There are Eastern and Western
Consortia for Proteomics Technologies currently character-
izing plasma samples from mouse models of colon, pan-
creatic, lung, and ovarian cancers.
2.2 Deducing potential protein biomarker candidates
from in vitro studies of tumor cell lines
Despite the lack of cellular heterogeneity so important in
tumors in vivo, it is useful to examine protein changes,
especially up-regulation, in tumor cell lines in vitro. An
example is the analysis of the epithelial-mesenchymal
transition (EMT) [22] in TGF-b-treated A549 human lung
adenocarcinoma cells [23]. This system is a model for the
transition of tumors from localized to an invasive and
metastatic phenotype, as bioassays show striking increases
in tumor cell motility and invasiveness. There are well-
established protein biomarkers for the EMT, namely down-
regulation of E-cadherin, up-regulation of N-cadherin, and
up-regulation of vimentin. Keshamouni et al. [23]
employed the iTRAQ method with isobaric tag reagents
[24]. The initial studies compared protein profiles after 72 h
of treatment with 5 ng/mL TGF-b versus baseline, using a
double-duplex design with the four tags, thereby facilitat-
ing significant improvement in the normalization of
quantitative results. With the ABI 4700 instrument for LC-
MS/MS, 29 proteins were identified as up-regulated and 22
as down-regulated (51 total vs. 16 expected by chance).
Proteins involved in cytoskeletal reorganization, including
actin, tubulin, and tropomyosins, and proteins involved in
cell motility, including integrin b-1, filamins, cofilin,
Hsp27 (HspB1), transglutaminase, and the ezrin-radixin-
moesin complex were up-regulated, while the down-regu-
lated proteins were more involved in cellular metabolism.
The cadherins and vimentin were not detected, which may
reflect concentration below the threshold for detection or
interference with detection of their peptides. Vimentin (but
not cadherins) and other additional proteins were identi-
fied in complementary proteomic analyses with DIGE and
SILAC methods, as reported at the US HUPO March 2006
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meeting. Elaborate combined time-course experiments
with both Affy analysis of mRNA and iTRAQ analysis of
proteins are pending. GeneGo Metacore pathways software
tools were applied to the proteomics findings, showing
significant connections among the up-regulated proteins
[23]. siRNA knockdown of HspB1 remarkably dissected
EMT into two phases, differentiating the down-regulation
of E-cadherin from the up-regulation of N-cadherin and
vimentin. Analysis of the literature revealed extensive evi-
dence that many of the up-regulated proteins are involved
in the biological processes modeled here (see Table 5).
Analyses of culture media will be performed to determine
which, if any, of these proteins are secreted or released in
sufficient amounts to be candidates for detection after
dilution in the plasma.
Many other interesting cell culture experiments have
reported major changes in protein expression. Lin et al. [3]
combined massively parallel signature sequencing (MPSS)
of mRNA transcripts with isotope-coded affinity tag (ICAT)
of the proteome to conduct a systems biology study of
androgen-perturbed LNCaP cells. The combined patterns
show functional differences between androgen-dependent
and androgen-independent prostate cancer cells. Gu et al.
[25] applied amino acid ICAT tagging to track p53-induced
apoptosis in colorectal cancer cells. Protein expression was
altered in multiple functional categories: cell cycle, mem-
branes, reactive oxygen species, glycolysis, ATP transport,
MMP induction, organelle cross-talk, and chaperones. Witt et
al. [26] utilized high throughput recombination-based clon-
ing of 1000 cDNAs relevant to breast cancers and a transla-
tional system to screen for proteins that mediate phenotypic
changes in three cell-based assays of mammary-10A tumor
cells expressing an ErbB2 variant; the assays were EGF-in-
dependent proliferation, disruption of acinar morphogen-
esis, and cell migratory behavior independently or coopera-
tively with ErbB2 activation.
Nishizuka et al. [27] characterized the NCI-60 cancer cell
lines with cDNA arrays, re-sequencing of the clones, and
corroboratation using Affymetrix oligonucleotide arrays. RP
proteomic arrays evaluated the selectivities of candidate bio-
markers at the protein level. Then tissue arrays were used to
demonstrate similar selectivity in clinical tumor specimens,
differentiating colon cancers from ovarian cancers and from
tumors of unknown primary site [28].
Technological advances are moving toward much more
sensitive detection of phosphorylation and other PTMs of
proteins in very small numbers of cells, using “ultra-micro-
arrays”, illustrated with PSA and IL-6 in ,100 LNCaP cells
[29]. Up to 17 properties, including signaling pathways, have
been measured in single cells with flow cytometry [30]. The
flow cytometry methods may turn heterogeneity of tumors
into an advantage, as different types of cells can serve as
comparisons or controls for the tumor cells or inflammatory
cells detected. These methods might also be enhanced suffi-
ciently to detect rare cancer cells in the circulation, as well as
cancer stem cells within the tumors.
Table 5. Correlation of TGF-beta-induced up-regulated proteins in A549 human lung adenocarcinoma cells with roles reported in human






Adhesion Migration Invasion Metastasis
Tropomyosins 1 1 1
Calgizzarin 1
Filamin A, B, and C 1 1 1 1
Integrin beta 1 1 1 1 1 1 1
HSPB1 1 1 1 1
Non-muscle myosin heavy polypeptide-9 1 1
Transglutaminase 2 1 1 1 1 1 1
Transgelin 2 1 1
Myosin alkali light chain 1 1 1 1
Radixin 1 1 1 1
Moesin 1 1 1 1
Desmoyokin 1 1
Cofilin 1 1 1
Glutathione transferase 1
14–3-3 zeta/delta 1 1 1 1
Keratin 1 1 1
Annexin A2 1 1 1 1
Actin, cytoplasmic 1 1 1
Tubulins 1 1 1
Histone H2A 1
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2.3 Detecting tumor proteins in plasma or serum
There are two general approaches: searching for proteins
already suspected or nominated as biomarker candidates
from tumor and tumor cell studies (above), and comparing
plasma or serum from cancer patients against specimens
from very well-matched non-cancer patients and normals to
detect proteome differences. Blood obtained by vene-
puncture is by far the most accessible human specimen,
least invasive, and feasible to monitor over long periods of
time. The blood plasma may capture proteins released from
all organs and tissues in health and disease. However,
plasma or serum presents certain daunting challenges: the
enormous complexity in numbers of proteins and protein
isoforms; the range of concentration from albumin at 40 mg/
mL to cytokines at 1 ng/mL and tissue proteins at even lower
concentrations; the dynamic changes in concentration,
structure, and function as a result of physiological, patho-
logical, and pharmacological triggers; and the necessity to
tradeoff extensive fractionation of intact proteins and of
peptides after tryptic digestion against higher throughput of
less fractionated specimens [1].
Proteins in the circulation that were released by tumors,
especially early-stage tumors, would be expected to have very
low concentrations. Proteins are susceptible to cleavage in
the circulation and during venepuncture, processing, and
storage. They are likely to be excreted by the kidney after fil-
tration through the glomeruli, if molecular weight is not
greater than 40 kDa. Low molecular weight proteins or pro-
tein fragments may be retained, however, if bound to albu-
min or other highly abundant proteins.
2.3.1 Targeting expected low-abundance
tumor-associated proteins
Existing protein biomarkers like prostate-specific antigen
(PSA), CA-125 for ovarian cancers, CA-19–9 for pancreatic
cancers, CEA for gastrointestinal cancers, and C-reactive
protein (CRP) for inflammatory conditions and acute cardi-
ovascular events are detected and quantitated with specific
immunoassays. Each assay required extensive work to opti-
mize conditions and reduce coefficient of variation. In prin-
ciple, the same kinds of assays can be applied to other tumor-
associated proteins shown to be secreted or released by
tumors and tumor cells. To study many proteins simulta-
neously, however, MS or antibody array methods are needed
[31]. Simultaneous optimization for many assays has not yet
been accomplished.
Anderson and Hunter [32] have introduced a quantitative
electrospray LC-MS/MS multiple reaction monitoring
(MRM) assay for pre-selected, protein-specific tryptic pep-
tides. Their proof-of-principle publication detected a few
dozen high and medium abundance proteins, from albumin
(40 mg/mL) to fibronectin (300 mg/mL) and a peptide from
L-selectin (670 ng/mL), quantitated with an ABI 4000 Q
TRAP hybrid triple quadrupole/linear IT instrument. The
peptide from L-selectin (AEIEYLEK) appears twice in the
HUPO PPP database, from two different labs, using two dif-
ferent citrate-anticoagulated reference specimens ([1]; see
PPP website). Peptides vary enormously in their detectability
in the mass spectrometer, so shrewd judgment and trial-and-
error are needed to maximize sensitivity of this approach.
Enrichment with stable isotope standards and capture with
anti-peptide antibodies (SISCAPA) can extend the range of
detection with this approach. These methods can be coupled
with survey methods and with miniaturization using beads
[33] or microarrays [34]. The instrumentation is widely avail-
able for assays of metabolites.
Aebersold has described a proteotypic peptide, isotope-
labeling approach focused on glycoproteins. This method is
well suited for spiking and quantitatively analyzing poten-
tially very large numbers of proteins [35, 36]. Enrichment of
glycoproteins in plasma has the special benefit of eliminat-
ing albumin, which has no sugars attached. The Hancock
and Aebersold labs, using complementary lectin-binding and
hydrazide methods, identified 264 glycoproteins with HUPO
reference specimens [1, 37]. This proteotypic peptide/glyco-
site method has particularly high potential for identifying
and quantifying proteins in a high throughput mode.
2.3.2 Detecting low-abundance tumor proteins,
protein fragments, or peptides bound to
abundant proteins
Petricoin et al. [38] described a method of biomarker ampli-
fication and harvesting from carrier molecules, colorfully
termed “molecular mops” or “molecular sponges” with their
“diagnostic cargo”. The concept is that protein fragments or
peptides, which would be eliminated through the kidney if
not bound, are retained and thereby amplified above their
concentration emerging from the tumor site, by being bound
to albumin or other highly abundant plasma proteins. A
variety of methods can be applied to detect the proteins,
ranging from a look-up table of m/z ratios and TOF for pre-
viously sequenced low molecular weight protein fragments
to MS/MS identification of previously unidentified frag-
ments. Some of these fragments may be low-abundance dis-
ease-related isoforms of high abundance proteins. The new
Orbitrap mass spectrometer seems to be well suited to these
analyses. Tryptic digestion can be bypassed, given the mostly
low Mr of fragments or peptides. However, the risk of errors
in protein identification is increased when proteolysis is due
to a diverse set of endogenous enzymes, rather than limited
to tryptic peptides.
2.3.3 Differences in the low molecular weight serum
peptidome
Villanueva et al. [39] published a surprising approach based
on what they interpreted to be primarily ex vivo proteolysis of
abundant peptides (Mr ,3000) in serum, generating heat
maps of specimens vs. peptide IDs. The patterns were nota-
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bly different, with some overlap, for sera from groups of
breast, bladder, and prostate cancer patients. This compar-
ison is a significant improvement over batch comparison of
each tumor type separately to various control groups. They
interpreted patterns to show ladders of cleavage products
from particular peptides, probably due to progressive cleav-
age by aminopeptidases and/or carboxypeptidases. They
identified fibrinopeptide A, C3f, and bradykinin as sources of
these peptidome differences with potential relevance in can-
cer biology. Their presumption is that proteases persist in the
sample (collected without protease inhibitors, of course) and
continue to act ex vivo. If so, defined, standardized scaffolds
might be more reliable substrates for such an assay of the
unidentified proteases than the highly variable fibrin clot.
What has long been treated as low molecular weight “noise”
may be appropriate for further research on diagnostic
potential [40]. In contrast, albumin-bound low molecular
weight fragments of BRCA2, tyrosine kinases, other signal-
ing molecules, and intracellular scaffolding proteins seem to
reflect in vivo proteolytic cleavages [41]. One might prefer
demonstration of in vivo proteolytic differences, as closer to
the biology. This focus on peptides produced during the
coagulation process requires serum specimens.
2.4 Autoantibodies to tumor proteins
There is no in vitro protein counterpart to PCR for amplifica-
tion of nucleic acids. However, the body has its own amplifi-
cation system for proteins, namely an antibody response
against epitopes on immunogenic tumor-associated proteins
[42]. This approach utilizes the natural biological amplifica-
tion of the immune response to generate immunoglobulin
biomarkers for specific tumor immunogens. Obviously, these
plasma or serum specimens should not be depleted of
immunoglobulins. Hanash et al. pioneered the use of West-
ern blots of 2-DE patterns from tumor cell lysates (A549) to
test for immunoreactivity with serum from patients. Brichory
et al. reported autoantibodies against annexin I and annexin II
[43] and later against PGP 9.5 [44] in 30–50% of patients with
adenocarcinomas of the lung, with high specificity. These
assays have not yet been extended or expanded sufficiently to
generate a panel for clinical evaluation, but the strategy is
promising. The Western blots require MS analysis of the
immunoreactive spots to determine what proteins can be
identified, followed by independent methods to confirm the
specificity of the autoantibody reactivity. Imafuku et al. [45]
summarized autoantibody markers reported for various can-
cers. For example, for pancreatic cancers, autoantibodies have
been reported against a truncated form of calreticulin [46],
MUC1 [47], p53 [48], and Rad51 [49]. No one has yet put these
and other candidate proteins together in a panel.
A complementary approach utilizes protein microarrays
instead of 2-D gel Western blotting [50]. Tumor lysate frac-
tions (A549 and H22 cell lines for lung cancer and LNCaP
cell lines for prostate cancer) have been spotted robotically
onto microarray slides after liquid-phase (IEF and HPLC)
fractionation. Haab has identified multiple spots with high
reproducibility in clusters of related fractions. The patterns
of immunoreactivity can be plotted on a heat map of frac-
tions vs. patients and normals to show the differences and
analyze for pattern differences between the groups for pros-
tate cancers. The patterns were strikingly different for sera
from patients with organ-confined prostate cancers vs. heal-
thy controls compared with sera from patients with meta-
static prostate cancer vs. the same healthy controls. Sub-
sequent studies have employed MS of the immunoreactive
spots to identify a protein or, often, a group of proteins that
may account for the immunoreactivity. Otherwise, the
results remain at the level of comparison of patterns between
cancer patient sera and sera of normal controls or patients
with other diseases [51].
Phage-display methods are another practical method for
screening for autoantibodies in cancer patients. Wang et al.
[52] employed this method to generate a detector panel of 22
phase-peptides and then autoantibody signatures that gave
remarkably good sensitivity and specificity for prostate can-
cer detection, far better than PSA (Fig. 4). As always, these
findings need confirmation in larger clinical studies. Four of
the 22 phage-peptides were confidently identified as proteins
involved in transcription or translation: bromodomain-con-
taining protein 2 (BRD2), eukaryotic translation initiation
factor 4 (eIF4G1), and ribosomal proteins L13a and L22.
These proteins are overexpressed in prostate cancer tumor
specimens, by Western blots, and in the Oncomine gene
expression database. Continuing work on this project is
generating identifications for additional proteins from the 22
peptides. Confirmation by independent groups is the next
step toward making this a useful test.
2.5 Identifying proteins from protein pattern screens
using ProteinChip SELDI-TOF-MS
Hundreds of papers have been published or presented using
a variety of chip surfaces for fractionation of serum, followed
directly by the SELDI method for MS. The first was a highly
publicized paper by Petricoin et al. [53] about ovarian cancer.
SELDI employs an artificial intelligence algorithm to com-
pare groups of samples from cancer cases versus normals,
generally finding that about 5 m/z peaks, among 15 000 or so
from low molecular weight fragments, could discriminate
the two groups with very high sensitivity and specificity.
However, the results were seldom confirmed by independent
groups, at least partly due to lack of reference standards and
specimens, lack of standard operating procedures, and rapid
changes in the MS technologies. The main proponents con-
ducted these assays in batches without cross-comparison of
results for different types of cancers. The NCI Early Detec-
tion Research Network invested significantly in this method
over several years (http://edrn.nci.nih.gov).
When m/z peaks were analyzed further to identify the
proteins responsible, high abundance host-response pro-
teins, or variants of those proteins, were usually found. For
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Figure 4. Receiver operator
characteristics (ROC) curves
based on multiplex analysis of
autoantibody signatures with
22-phage-peptide detector
panel, compared with PSA, for
60 prostate cancer patients and
68 controls. The red line is the
phage-peptide-detector; the
green line is the PSA test. The
middle and right panels restrict
the analysis to patients with PSA
levels between 4 and 10 ng/mL,
and 2.5 and 10 ng/mL, respec-
tively, the critical zone for clinical
decision-making. (Adapted from
[52], with permission).
example, a thermostable variant of serum amyloid A1 was
identified after analysis with the Ciphergen ProteinChip
SELDI-TOF MS method in sera from 15 of 27 ovarian cancer
patients, compared with 2 of 34 normal women. There was a
double peak at 11.68 kDa and 11.52 kDa; the smaller peak is
its N-terminal Arg-truncated isoform [54]. Incidentally, the
heating step (10 min at 987F) precipitated and removed the
albumin.
Zhang et al. [55] reported a set of three discriminating
peaks from a SELDI study of 153 patients with stage III
invasive epithelial ovarian cancer, compared with 142 healthy
women, 166 with benign pelvic masses, and 42 with other
ovarian cancers. Results from two centers were confirmed
with analyses of women from two other centers and then
immunoassays of sera from a fifth center. MS showed the
three peaks to be an increase of inter-a trypsin inhibitor
heavy chain H4, decrease of a truncated form of transthyr-
etin-10, and decrease of apolipoprotein A-1. These three
marker candidates enhanced the sensitivity of CA-125 at a
pre-determined specificity of 97% in patients with early-stage
invasive ovarian cancers. So far, further validation and appli-
cation of these findings have not been reported.
As the most lethal of cancers, pancreatic cancers are par-
ticularly cogent as a target for new diagnostic markers. From
a SELDI-TOF analysis of 245 plasma samples from patients
and controls [56], four m/z peaks were sufficient to dis-
criminate pancreatic cancer from normals in the training
and then testing format, with a claimed sensitivity of 91%,
which increased to 100% when combined with CA-19–9, but
with a false-positive rate of 19%, which would dominate any
screening application. The authors rejected a peak probably
due to serum amyloid A, but were not able to identify any of
the four peaks reported. Bloomston et al. [57] utilized auto-
mated ProGEx 2-DE with 32 normal and 30 pancreatic can-
cer serum specimens; of 1744 protein spots, 154 were com-
monly overexpressed in cancer patient samples, of which 9
with just 4 identifications (two fibrinogen g chain, comple-
ment factor B, and plasminogen) were reported as sufficient
to discriminate 30/30 cancer and 30/32 control sera. Fibrin-
ogen g may be important in the clinically observed hyper-
coagulability of the blood in such patients.
Similar results were obtained using 2-D gels in a study of
pooled sera from 20 late-stage lung cancer patients and 20
healthy matched male donors in the Domont laboratory in
Brazil [58]. Transthyretin monomer, haptoglobin-a 2, and
two isoforms of serum amyloid protein, as well as Ig l chain,
were up-regulated. A fragment of apolipoprotein A-1 was
down-regulated in patients. Probably more systematic atten-
tion should be directed at these abundant proteins and their
low-molecular weight conformers.
It has long been known that inflammatory or cellular
stress responses somehow increase the concentrations of
relatively abundant circulating proteins, so-called “acute-
phase reactants”. Many conditions trigger increases in such
proteins as haptoglobin, a-1 anti-trypsin, serum amyloid A,
transthyretin, and CRP. Nevertheless, in appropriate diag-
nostic situations, a rapid increase in concentrations or high
measured level of these readily detected proteins may be
helpful in guiding further diagnostic work-up for cancers,
myocardial infarction, flares of rheumatoid arthritis, or other
conditions.
PTMs may make these proteins more specific markers.
The most serious flaw in this blind-screening approach is
the enormous number of comparisons tested, which should
require a Bonferroni-type adjustment that would drastically
reduce the statistical significance of the findings. Without
identification of the proteins accounting for the m/z peaks, it
is hard to interpret the results. Without reliable confirmation
of the findings with additional sets of patients and in inde-
pendent laboratories, the clinical value could not be demon-
strated. There were two interlab comparison projects, one led
by the NCI Early Detection Research Network [59] and one by
the HUPO Plasma Proteome Project [60], which did show
rather good correlation of m/z peak findings with the same
reference specimens in several participating labs when com-
plying with a common protocol.
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2.6 Detection of differences in abundant proteins
with antibody microarrays
Gao et al. [61] reported results from microarrays prepared by
Haab with 84 antibodies in triplicate, against mostly abun-
dant proteins. The antibody arrays were reacted with sera
from 24 patients with adenocarcinoma of the lung, 32
patients with chronic obstructive lung disease, and 24 nor-
mal controls. Using a cut-off on immunoreactivity at which
all 56 controls were non-reactive, the microarrays were able
to identify 15 of the 24 lung cancer patients (62% sensitivity).
As shown in Table 6, the most discriminating proteins were
CRP (13-fold increase), serum amyloid A (2-fold increase),
MUC1 (1.3–1.4-fold increase), and two isoforms of a-1 anti-
trypsin (1.4-fold increase), while transferrin and gelsolin
were decreased. We do not know whether the proteins were
modified or intact.
Using a very similar set of 92 antibodies, the Haab
laboratory probed sera from 61 pancreatic cancer patients,
31 patients with benign pancreatic disease, and 50 healthy
controls in replicate experiments with the two-color, rolling
circle amplification method. The proteins detected with
reproducibly different binding levels between the patient
classes reflected inflammation (high CRP, a-1-antitrypsin,
and serum amyloid A), immune response (high IgA),
leakage of cell breakdown products (low plasma gelsolin),
and possibly altered vitamin K usage or glucose regulation
(high protein-induced vitamin K antagonist-II). Results
were confirmed with immunoblot and antigen dilution
experiments. A logistic-regression algorithm distinguished
the cancer samples from the healthy control samples with
90% and 93% sensitivity and 90% and 94% specificity in
duplicate experiments. The cancer samples were dis-
tinguished from the benign disease samples with 95% and
92% sensitivity and 88% and 74% specificity in duplicate
experiment sets. The classification accuracies were signifi-
cantly improved over those achieved using individual anti-
bodies [62].
As noted above, numerous studies have reported acute-
phase reactant proteins as potential biomarkers. Perhaps
combinations of these should be evaluated in a multi-center
study of several types of tumors.
3 Confirming and validating protein
biomarker candidates and panels of
biomarkers
The National Cancer Institute Early Detection Research Net-
work set up a well-defined multi-stage scheme for discovery
and validation of potential biomarkers several years ago. So
far, few have made it past the discovery phase to replication
in the same laboratory and then replication in a second lab-
oratory. A much more complex stage of clinical validation
then must follow, with appropriate screening scenarios to
test and determine sensitivity, specificity, and positive pre-
dictive value in large populations. Guidance on proper epi-
demiological methodology and avoidance of bias and over-
fitting of results has been published recently by Ransohoff
[63, 64] and Ioannidis [65]. Stratification of patients on clin-
ical, pathological, or genetic criteria may be essential to
account for the expected heterogeneity of mechanisms and,
therefore, biomarkers in common cancers and other dis-
eases. Therefore, sensitivity should not be expected to
approach 100% for any one marker or even for a panel of very
good markers. For screening purposes, the specificity must
be as high as possible, to avoid false-positives, while still
making the cut-off for quantitative differences appropriate
for useful sensitivity as a screening test, avoiding many false-
negatives, i.e., missed diagnoses. The parameters for mon-
itoring already diagnosed patients are quite different, since
the diagnosis is already established, in contrast to a 4 in
10 000 incidence rate for ovarian cancer, for example, in adult
female populations.
Due to heterogeneity of tumors and patients, and based
on the extensive experience of recent years, it is unlikely that
any single protein will be a highly predictive biomarker,
especially in the screening scenario. More likely, a panel of
several biomarkers will be required to achieve sufficient
sensitivity to be useful for screening. The discovery of each of
these candidates may come from different strategies. Opti-
mization of such panels will be a complex challenge, seeking
increasing sensitivity while keeping specificity high, to
achieve useful predictive value for screening [63–65]. Multi-
plex ELISA and protein chip microarrays offer high
throughput, but immunoassays in general may be incapable
Table 6. Antibody microarrays for abundant proteins differentiate lung cancer patients from controls (from [61])
Antibody Fold difference in means P-values from 1-way ANOVA
Tumor / Normal Tumor / COPD Tumor vs. Normal Tumor vs. COPD
CRP 13.6 13.0 1.161022 2.2610210
SAA 1.99 2.15 1.861022 1.761029
MUC1 1.30 1.42 3.361023 4.361025
AAT (1) 1.34 1.35 9.161024 3.161024
AAT (2) 1.42 1.33 1.161024 3.761023
Transferrin 0.73 0.71 2.761024 2.361023
Gelsolin 0.77 0.77 5.861023 4.761023
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of differentiating size isoform variants. If no new epitope is
formed, how will the immunoassay-based methods differ-
entiate the variants? Automated combinations of immu-
noassays or chromatography with MS may provide such dif-
ferentiation and identification. Instruments for 2-D LC-MS/
MS that combine precise elution times with high mass
accuracy will permit higher throughput identification of
peptides and proteins using primarily LC-MS parameters.
Instead of “geographical” classification of cancers by
organ of origin in the body, we will have molecular informa-
tion with which to begin to classify tumors according to the
mechanism that led to the tumor, which should be the basis
for its selective treatment even before it can be detected with
imaging. Combining the molecular marker with imaging
techniques, perhaps utilizing nanoparticles, is a com-
plementary path.
Leading journals and scientists have agreed that far more
documentation is required for proteomics publications, both
in the print version and the supplementary material, with
guidelines now available [66] that should also inform the
design of the whole study. There is also renewed attention at
the National Cancer Institute, the National Institute for
Standards and Technology, and various scientific societies to
develop reference standards of peptides, proteins, and clin-
ical specimens [67].
4 Comments
The need for reliable biomarkers for early diagnosis of var-
ious cancers remains compelling. Progress on prevention of
clinical manifestations and on survival of those diagnosed
with clinical cancers depends on such biomarkers. In some
cases, like lung cancers, where there is a large-scale screen-
ing program with spiral CT scanning of the chest in 50 000
participants at increased risk due to cigarette smoking his-
tories, molecular markers could be combined with imaging
protocols to enhance clinical decision-making and improve
cost-effectiveness of the total program.
The direct comparison of plasma or serum from
patients and controls has not proved very productive in
terms of reproducible results or practical diagnostic screen-
ing tests. Neither has the analysis of tumor specimens for
mRNA or protein differences between cancers and normal
or benign tissues. Part of the problem may be lack of atten-
tion to details of specimen collection, choice of controls,
early replication, and exchange of reagents and specimens.
Part of the challenge is setting specific criteria for the dif-
ferent kinds of assays for tumor-associated biomarkers in
plasma, ranging from proteins secreted or released from the
tumor to highly abundant acute-phase reactants and from
normal proteins to proteins that may have specific and
potentially diagnostic modifications. Several types of refer-
ence standards – peptides, proteins, and clinical specimens
– will help calibrate instruments and quantitate proteins
identified.
Furthermore, there is a greater appreciation now of the
essential criteria for independent confirmation and then
large-scale validation and of the necessity of anticipating
heterogeneity among patients with a common diagnosis.
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